Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 46,375

Document Document Title
WO/2014/025808
Provided herein are curcumin analogues that are able to interact with amyloid β (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds in the treatment of Alzheimer's Disea...  
WO/2014/025679
The present invention is directed to a process for the preparation of heterocyclic derivatives of formula I (I), wherein J, X, Z, W and R2 are as defined herein using a palladium catalysed aminocarbonylation reaction. Such compounds are ...  
WO/2014/025993
D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as thera...  
WO/2014/022879
The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment...  
WO/2014/025019
Provided is a means for improving breeding performance of industrial animals. This animal feed is provided to industrial animals to raise the industrial animals, and is characterized by containing L-valine and L-lysine, and having a mass...  
WO/2014/025202
The present invention relates to a pharmaceutical composition or a functional food composition comprising a mixed extract of Zingiber officinale ROSC and Paeonia lactiflora Pallas as an active ingredient for preventing or treating dement...  
WO/2014/023860
The aim of the invention is the treatment of neurodegenerative diseases or other applicable pathologies by means of the intranasal application of a composition obtained from at least one blood compound and having growth factors, or by me...  
WO/2014/025905
In certain embodiments multi-component formulations are provided where the formulations comprise a first component comprising one or more vitamins selected from the group consisting of one or more B vitamins, vitamin C, vitamin D, vitami...  
WO/2014/026164
There are dynamic interdependence and complex signaling between all of the brain's cellular elements such as glia and especially oligodendrocytes. The evidence suggests that aspects of the human brain such as myelin and the homeostatic r...  
WO/2014/025942
This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain em...  
WO/2014/025651
Chroman compounds and derivatives of Formula (I) are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical composit...  
WO/2014/023191
Disclosed are an N-substituted pyrazolo [3, 4-d] pyrimidine ketone compound, a preparation method therefore and application thereof as an inhibitor for phosphodiesterase IX (PDEIX). In Formula (I), R' is selected from isopropyl, cyclopen...  
WO/2014/023674
The present invention relates to compounds of general formula (I), wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, lower alkyl or lower alkyl substituted by haloge...  
WO/2014/024993
Provided is a compound having an antagonistic activity on an arginine-vasopressin 1b receptor. A compound represented by general formula (I) [wherein each symbol is as defied in the description] or a salt thereof has an antagonistic acti...  
WO/2014/023385
Compounds of the formula (I) in which R, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus  
WO/2014/025905
In certain embodiments multi-component formulations are provided where the formulations comprise a first component comprising one or more vitamins selected from the group consisting of one or more B vitamins, vitamin C, vitamin D, vitami...  
WO/2014/023390
Compounds of the formula (I), in which R1, X, Y and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central ne...  
WO/2014/020405
The disclosure relates to Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein R1, R2, Qa, Y1, Z, A, B, Qx, E, G, J, M, U, W, and a are as de...  
WO/2014/021393
The present invention relates to a transdermal absorption-type pharmaceutical preparation having improved zonisamide cutaneous permeation. This transdermal absorption-type pharmaceutical preparation is characterized by containing (i) zon...  
WO/2014/020480
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/019268
A pharmaceutical composition for promoting nerve injury restoration and an application thereof. The pharmaceutical composition in each unit contains 0.5-8g of L-ornithine, 1-5g of aspartic acid, 3-10g of arginine, and 3-10g of vitamin B6...  
WO/2014/019023
The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention als...  
WO/2014/022570
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition comprises a multiparticulate modified releas...  
WO/2014/022340
This invention relates the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions...  
WO/2014/022841
The invention provides for methods of treating lysosomal storage disorders and/or reduction of non-cholesterol lipids, using cyclodextrin compounds, including in combination with other therapeutics, including vitamin E.  
WO/2014/022143
The use of ORL-1 receptor antagonists of the formula (I) for the treatment of anxiety disorders is described.  
WO/2014/021337
The present invention provides a compound and pharmaceutical composition for a neuropsychological disorder or malignant tumor, the use thereof, and a method for preventing, improving, inhibiting the progression of and/or treating a neuro...  
WO/2014/020608
A method of treating a motor neuron disease (MND) in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of enhancing processing of a pre-mi RNA...  
WO/2014/021455
Provided is a medicine which can be widely used for intractable neurological disorders, inflammatory diseases, etc. This immune cell activation inhibitor is characterized in comprising bromovalerylurea or a derivative thereof. This immun...  
WO/2014/019468
Provided is a piperazinotrizole compound represented by general formula I or an isomer, a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof. Also provided are a method for preparing the compound, a drug composition cont...  
WO/2014/019092
The present application relates to imidazolidinecliones, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullinat...  
WO/2014/019979
The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other disease...  
WO/2014/021273
The morphinan derivatives represented by general formula (I) (wherein: R1 represents a cycloalkyl alkyl, an aralkyl, or the like; R2 represents an aralkyl, a heteroaryl alkyl, or the like; R3, R4 and R5 represent hydrogen, a hydroxy, or ...  
WO/2014/019855
The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group...  
WO/2014/022167
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2014/016267
The present invention relates to compounds of general formula (I) wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptab...  
WO/2014/017593
A production method for an adhesive patch comprising a supporting body layer and an adhesive layer, said production method including: a mixture preparation step in which asenapine or a pharmacologically acceptable salt thereof and a sodi...  
WO/2014/016789
A compound of the general formula (I) wherein R1 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, CN, -O-C1-C3-alkyl, fluorinated -O-C1-C3-alkyl, -(CH2)mOH ...  
WO/2014/015436
The present disclosure provides for an apparatus and related method for controlling the rate of nicotine delivery into systemic circulation of a subject. The method comprises transdermally administering nicotine at a topical administrati...  
WO/2014/018570
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine -γ-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other com...  
WO/2014/017462
It is now revealed that the amount of syntenin protein is increased in tuberous sclerosis. It is now also revealed that the binding between syndecan-2 protein, which is a protein known as a factor capable of inducing the formation of spi...  
WO/2014/015993
The present invention relates to compounds of formula (I) having a bicyclic aza-amides scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together wit...  
WO/2014/018741
In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure rela...  
WO/2014/017594
An adhesive patch comprising a supporting body layer and an adhesive layer. The adhesive layer contains asenapine and/or a pharmacologically acceptable salt thereof, isopropyl palmitate, and an adhesive base.  
WO/2014/015523
The invention relates to novel heteroaryl and heterocycle compounds and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3k and for treating inflammatory and autoimmune disorders dise...  
WO/2014/016003
The invention relates to the use of biotin for treating multiple sclerosis, in particular of the progressive forms and of the neurological sequelae.  
WO/2014/017569
A pharmaceutical product for lowering blood LDL, which is a pharmaceutical product that contains a compound represented by formula (I) as an active ingredient, said compound having actions of inhibiting the expression of PCSK9mRNA, lower...  
WO/2014/017243
The purpose of the present invention is to provide a sleep quality improving agent which has a satisfactory sleep quality improving effect, can exert the effect through oral administration in any dosage form, and has ensured safety to th...  
WO/2014/018563
Described herein are methods for the treatment of cancers, particularly neuroendocrine tumors. Also described herein are methods for selecting drug candidates for the treatment of cancers such as neuroendocrine tumors.  
WO/2014/018571  

Matches 701 - 750 out of 46,375